Modulators of dyslipidaemia

Bibliography

• 1997 Heart and Stroke Statistical Update. American Heart Association. Dallas, TX. (http: //www.americanheart.org).
   Google Scholar
• INTERNATIONAL LIPID INFORMATION BUREAU: Blood lipids and coronary heart disease. In: The ILIB Lipid Handbook for Clinical Practice. Morris Plains, NJ (1995).
   Google Scholar
• NATIONAL CHOLESTEROL EDUCATION PROGRAM: Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Second report of the National Cholesterol Education Program (NCEP). Circulation (1994) 89:1329–1445.
   Web of Science ®Google Scholar
• SUPERKO HR: The atherogenic lipoprotein profile. Sci. Med. (1997):36–45.
   Web of Science ®Google Scholar
• PATSCH W, GOTTO AM, Jr.: High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. Adv. Pharmacol. (1995) 32:375–426.
   PubMedGoogle Scholar
• WILT VM, GUMS JG: 'Isolated' low high-density lipoprotein cholesterol. Ann. Pharmacother. (1997) 31:89–97.
   PubMed Web of Science ®Google Scholar
• VEGA GL, GRUNDY SM: Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr. Opin. Lipidol. (1996) 7:209–216.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D: The Veterans Affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am. J. Cardiol. (1996) 78:572–575.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM: Small LDL, atherogenic dyslipidaemia, and the metabolic syndrome. Circulation (1997) 95:1–4.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Role of insulin resistance in human disease (Syndrome X): an expanded definition. Ann. Rev. Med. (1993) 44:121–131.
   PubMed Web of Science ®Google Scholar
• Woodford FP, Davignon J, Sniderman A (Eds.), Elsevier Science BV, Amsterdam (1995): 516–519.
   Google Scholar
• Woodford FP, Davignon J, Sniderman A (Eds.), Elsevier Science BV, Amsterdam (1995):520–524.
   Google Scholar
• SEMPOS CT, CLEEMAN JI, CARROLL MD, et al.: Prevalence of high blood cholesterol among US adults. An update on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. J. Am. Med. Assoc. (1993) 269:3009–3014.
   PubMed Web of Science ®Google Scholar
• BAYS HE, DUJOVNE CA, LANSING AM: Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis. Stroke (1992) 1:357–365.
   PubMedGoogle Scholar
• RUBINS HB, ROBINS SJ, COLLINS D, et al.: Distribution of lipids in 8500 men with coronary artery disease. Am. J. Cardiol. (1995) 75:1196–1201.
   PubMed Web of Science ®Google Scholar
• Gilman AG, Goodman LS, Rall TW, Murad F (Eds.), MacMillan Publishing Co., NY (1985) Chapter 34:827–845.
   Google Scholar
• LIPID RESEARCH CLINICS PROGRAM: The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Assoc. (1984) 251:351–374.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, NESSIM SA, JOHNSON RI, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J. Am. Med. Assoc. (1987) 257:3233–3240.
   PubMed Web of Science ®Google Scholar
• THE LOVASTATIN GROUP III: A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolaemia. J. Am. Med. Assoc. (1988) 260:359–366.
   PubMed Web of Science ®Google Scholar
• TONSTAD S: A rational approach to treating hypercholesterolaemia in children. Weighingthe risks and benefits. Drug Safety (1997) 16:330–341.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• SACKS, FM, PFEFFER MA, MOYE LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• LEA AP, MCTAVISH D: Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs (1997) 53:828–847.
   PubMed Web of Science ®Google Scholar
• NAWROCKI JW, WEISS SR, DAVIDSON MH, et al.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. (1995) 15:678–682.
   PubMed Web of Science ®Google Scholar
• BAKKER-ARKEMA RG, DAVIDSON MH, GOLDSTEIN RJ, et al.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridaemia. J. Am. Med. Assoc. (1996) 275:128–133.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO 0, HAAPA K, et al.: Helsinki heart study: primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia. New Engl. J. Med. (1987) 317:1237–1245.
   PubMed Web of Science ®Google Scholar
• ERICSSON CG, HAMSTEN A, NILSSON J, et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet (1996) 347:849–853.
   PubMed Web of Science ®Google Scholar
• FRICK MH, SYVANNE M, NIEMINEN MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation (1997) 96:2137–2143.
   PubMed Web of Science ®Google Scholar
• CORONARY DRUG PROJECT RESEARCH GROUP: Clofibrate and niacin in coronary heart disease. J. Am. Med. Assoc. (1975) 231:360–381.
   PubMed Web of Science ®Google Scholar
• CANNER PL, BERGE KG, WENGER NK, et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. (1986) 8:1245–1255.
   PubMed Web of Science ®Google Scholar
• PASTERNAK RC, BROWN LE, STONE PH, et al.: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and 'normal' cholesterol levels. Ann. Intern. Med. (1996) 125:529–540.
   PubMed Web of Science ®Google Scholar
• IMS, Midas database (1997).
   Google Scholar
• BILLHEIMER J, FISCHER F, GERMAIN S, et al.: DMP-504: a hydrogel bile acid sequestrant: Part 2- Mechanism of action studies in the hamster. Twelfth International Symposium on Drugs Affecting Lipid Metabolism. Houston, TX (1995):139.
   Google Scholar
• MANDEVILLE WH, GOLDBERG DI.: The sequestration of bile acids, a non-absorbed method for cholesterol reduction. A review. Curr. Pharm. Design (1997) 3:15–28.
   Web of Science ®Google Scholar
• HOMMA Y, KOBAYASHI T, OZAWA H, et al.: Effects of a new bile acid sequestering resin, MCI-196, on plasma lipoprotein subfractions. Twelfth International Symposium on Drugs Affecting Lipid Metabolism. Houston, TX (1995)59.
   Google Scholar
• HAYVVARD CM, HAMANAKA ES, AIELLO RJ, et al.: Discovery of the squalene synthetase inhibitor CP-340868. Atherosclerosis (1997) 134:125.
   Google Scholar
• HARRITY TW, GEORGE RJ, CIOSEK CP, et al.: BMS-188494, an orally active squalene synthase inhibitor which lowers cholesterol in animals. Twelfth International Symposium on Drugs Affecting Lipid Metabolism. Houston, TX (1995) 54.
   Google Scholar
• DICKSON JK, BILLER SA, MAGNIN DR, et al.: Orally active squalene synthetase inhibitors: Bis((acyloxy) alkyl) prodrugs of the a-phosphonosulfonic acid moiety. J. Med. Chem. (1996) 39:661–664.
   PubMed Web of Science ®Google Scholar
• HARWOOD HJ JR., CHANDLER CE, PELLARIN LD, et al.: Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin 0- tigogenin cellobioside (CP-88818; tiqueside). J. Lipid Res. (1993) 34:377–395.
   PubMed Web of Science ®Google Scholar
• HARRIS WS, DUJOVNE CA, WINDSOR SL, et al.: Inhibiting cholesterol absorption with CP-88818 (0-tigogenin cellobioside; Tiqueside): studies in normal and hyperlipidaemic subjects. J. Cardiovasc. Pharmacol. (1997) 30:55–60.
   PubMed Web of Science ®Google Scholar
• MCCARTHY PA, DENINNO MP, MOREHOUSE LA, et al.: 11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster. J. Med. Chem. (1996) 39:1935–1937.
   PubMed Web of Science ®Google Scholar
• HARRIS WS, WINDSOR SL, NEWTON FA, et al.: Inhibition of cholesterol absorption with CP-148623 lowers serum cholesterol in humans. Clin. Pharmacol. Ther. (1997) 61:385–389.
   PubMed Web of Science ®Google Scholar
• SALISBURY BG, DAVIS HR, BURRIER RE, et al.: Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, Sch48461. Atherosclerosis (1995) 115:45–63.
   PubMed Web of Science ®Google Scholar
• VAN HEEK M, FRANCE CF, COMPTON DS, et al.: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther. (1997) 283:157–163.
   PubMed Web of Science ®Google Scholar
• ROTH BD: ACAT inhibitors: evolution from cholesterol absorption inhibitors to antiatherosclerotic agents. Drug Disc. Today (1998) 3:19–25.
   Web of Science ®Google Scholar
• HOMAN R, KRAUSE BR.: Established and emerging strategies for inhibition of cholesterol absorption. Curr. Pharm. Design. (1997) 3:29–44.
   Web of Science ®Google Scholar
• WETTERAU JR, LIN MCM, JAMIL H: Microsomal triglyceride transfer protein. Biochim. Biophys. Acta (1997) 1345: 136–150.
   Google Scholar
• GORDON DA, WETTERAU JR, GREGG RE: Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles. Trends Cell Biol. (1995) 5:317–321.
   PubMed Web of Science ®Google Scholar
• WETTERAU JR, AGGERBECK LP, BOUMA ME, et al.: Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinaemia. Science (1992) 258:999–1001.
   PubMed Web of Science ®Google Scholar
• JAMIL H, GORDON DA, EUSTICE DC, et al.: An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from Hep-G2 cells. Proc. Natl. Acad. Sci. USA (1996) 93:11991–11995.
   PubMed Web of Science ®Google Scholar
• RADER DJ, BREWER HB, Jr.: Abetalipoproteinemia. New insights into lipoproteinassembly and vitamin E metabolism from a rare genetic disease. J. Am. Med. Assoc. (1993) 270:865–869.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee #67 Meeting on Orlistat (XenicaL tetrahydrolipstatin). Bethesda, MD (14 May 1997).
   Google Scholar
• AVIRAM M, LUBOSHITZKY R, BROOK JG: Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapy. Clin. Biochem. (1982) 15:62–66.
   PubMed Web of Science ®Google Scholar
• LEESON PD, EMMETT JC, SHAH VP, et al.: Selective thyromimetics. Cardiac-sparing thyroid hormone analogues containing 3'-arylmethyl substituents. J. Med. Chem. (1989) 32:320–336.
   PubMed Web of Science ®Google Scholar
• HANSSON P, VALDERMARSSON S, NILSSON-EHLE P: Experimental hyperthyroidism in man: effects on plasma lipoproteins, lipoprotein lipase and hepatic disease. Hormone Metab. Res. (1983) 15:449–452.
   PubMed Web of Science ®Google Scholar
• PACKARD CJ, SHEPHERD J, LINDSAY GM, et al.: Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J. Clin. Endocr. Metab. (1993) 76:1209–1216.
   PubMed Web of Science ®Google Scholar
• OPPENHEIMER JH, SCHWARTZ HL, MARIASH CN, et al.: Advances in our understanding of thyroid hormone action at the cellular level. Endocrinol. Rev. (1987) 8:288–308.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD AH, EMMETT JC, ELLIS D, et al.: A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature (1986) 324:425–429.
   PubMed Web of Science ®Google Scholar
• SOYAL SM, SEELOS C, LIN-LEE YC, et al.: Thyroid hormone influences the maturation of apolipoprotein Al mRNA in rat liver. J. Biol. Chem. (1995) 270:3996–4004.
   PubMed Web of Science ®Google Scholar
• NESS GC, LOPEZ D: Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7a-hydroxylase by thyroid hormone. Arch. Biochem. Biophys. (1995) 323:404–408.
   PubMed Web of Science ®Google Scholar
• MOORADIAN AD, WONG NCW, SHAH GN: Age-related changes in the responsiveness of apolipoprotein Al to thyroid hormone. Am. J. Physiol. (1996) 271:R1602–R1607.
   PubMed Web of Science ®Google Scholar
• RID GEWAY ND, DOLPHIN PJ: Serum activity and hepatic secretion of LCAT in experimental hypothyroidism and hypercholesterolaemia. J. Lipid Res. (1985) 26:1300–1313.
   PubMed Web of Science ®Google Scholar
• HULSMANN WC, OERLEMANS MC, GEELHOED-MIERAS MM: Effect of hypothyroidism, diabetes and polyunsaturated fatty acids on heparin-releasable rat liver lipase. Biochem. Biophys. Res. Commun. (1977) 79:784–788.
   PubMed Web of Science ®Google Scholar
• SEVERSON DL, FLETCHER T: Effect of thyroid hormones on acid cholesterol ester hydrolase activity in rat liver, heart and epididymal fat pads. Biochim. Biophys. Acta (1981) 675:256–264.
   PubMed Web of Science ®Google Scholar
• Thyrotoxicosis. Disease of the Month (1997) 43:601–680.
   PubMedGoogle Scholar
• POLIKAR R, BURGER AG, SCHERRER U, et al.: The thyroid and the heart. Circulation (1993) 87:1435–1441.
   PubMed Web of Science ®Google Scholar
• WARTOFSKY L, INGBAR L: Diseases of the thyroid. In: Harrison's Principles of Internal Medicine (Twelfth Edition). Wilson JE, Braunwald E, Isselbacher KJ et al. (Eds.), McGraw Hill, Inc., NY (1991) Chapter 316:1692–1712.
   Google Scholar
• IOSSA S, MOLLICA MP, LIONETTI L, et al.: Effect of a high fat diet on energy balance and thermic effect of food in hypothyroid rats. Eur. J. Endocrinol. (1997) 136:309–315.
   PubMed Web of Science ®Google Scholar
• TAYLOR AH, STEPHAN ZF, STEELE RE, et al.: Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Mol. Pharmacol. (1997) 52:542–547.
   PubMed Web of Science ®Google Scholar
• STEPHAN ZH, YURACHEK EC, SHARIF R, et al.: Demonstration of potent lipid-lowering activity of a thyromimetic agent devoid of cardiovascular and thermogenic effects. Atherosclerosis (1996) 126:53–63.
   PubMed Web of Science ®Google Scholar
• Woodford FP, Davignon J, Sniderman A (Eds.), Elsevier Science By, Amsterdam (1995):321–324.
   Google Scholar
• MORGAN JM, CHANG SW, LINBERG L: Single dose safety, tolerability and pharmacokinetics of CGS-26214 in healthy males. J. Clin Pharmacol. (1997) 37:858.
   Web of Science ®Google Scholar
• NATHAN L, CHAUDHURI G: Estrogens and atherosclerosis. Ann. Rev. Pharmacol. Toxicol. (1997) 37:477–515.
   PubMed Web of Science ®Google Scholar
• GRANFONE A, CAMP OS H, MCNAMARA JR, et al.: Effects of oestrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism (1992) 41:1193–1198.
   PubMed Web of Science ®Google Scholar
• KUIPER GGJM, GUSTAFSSON JA: The novel estrogen receptor-f3 subtype: potential role in the cell- and promoter-specific actions of estrogens and antiestrogens. FEBS Lett. (1997) 410:87–90.
   PubMed Web of Science ®Google Scholar
• PARINI P, ANGELIN B, RUDLING M: Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1800–1805.
   PubMed Web of Science ®Google Scholar
• PETTERSSON K, GRANDIEN K, KUIPER GGJM, et al.: Mouse estrogen receptor f3 forms estrogen response element-binding heterodimers with estrogen receptor a. Mol. Endocrinol. (1997) 11:1486–1496.
   PubMed Web of Science ®Google Scholar
• WATANABE T, INOUE S, OGAWA S, et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors a and 0. Biochem. Biophys. Res. Commun. (1997) 236:140–145.
   PubMed Web of Science ®Google Scholar
• PAECH K, WEBB P, KUIPER GGJM, et al.: Differential ligand activation of estrogen receptors ERa and ERf3 at AP1 sites. Science (1997) 277:1508–1510.
   PubMed Web of Science ®Google Scholar
• IAFRATI MD, KARAS RH, ARONOVITZ M, et al.: Estrogen inhibits the vascular injury response in estrogen receptor a-deficient mice. Nature Med. (1997) 3:545–548.
   PubMed Web of Science ®Google Scholar
• PACE P, TAYLOR J, SUNTHARALINGAM S, et al.: Human estrogen receptor 13 binds DNA in a manner similar to and dimerizes with estrogen receptor a. J. Biol. Chem. (1997) 272:25832–25838.
   PubMed Web of Science ®Google Scholar
• DRAPER MW, FLOWERS DE, HUSTLER WJ, et al.: A controlled trial of raloxifene (LY139481) HC1: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. (1996) 11:835–842.
   PubMed Web of Science ®Google Scholar
• SAARTO T, BLOMQVIST C, EHNHOLM C, et al.: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. (1996) 14:429–433.
   PubMed Web of Science ®Google Scholar
• SULLIVAN JM: Estrogen replacement. Circulation (1996) 94:2699–2702.
   PubMed Web of Science ®Google Scholar
• ROSSOUW JE: Estrogens for prevention of coronary heart disease. Putting the breaks on the bandwagon. Circulation (1996) 94:2982–2985.
   PubMed Web of Science ®Google Scholar
• LEMBERGER T, DES VERGNE B, WAHLI W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann. Rev. Cell Dev. Biol. (1996) 12:335–363.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, MARTIN G, STAELS B, et al.: Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. (1997) 8:159–166.
   PubMed Web of Science ®Google Scholar
• STAELS B, AUWERX J: Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharm. Design (1997) 3:1–14.
   Web of Science ®Google Scholar
• SCHOONJANS K, STAELS B, AUWERX J: The peroxisome proliferator-activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta (1996) 1302:93–109.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, SUNDSETH SS, JONES SA, et al.: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and y. Proc. Natl. Acad. Sci. USA (1997) 94:4318–4323.
   PubMed Web of Science ®Google Scholar
• FORMAN BM, CHEN J, EVANS RM: Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors a and S. Proc. Natl. Acad. Sci. USA (1997) 94:4312–4317.
   PubMed Web of Science ®Google Scholar
• KREY G, BRAISSANT 0, L'HORSET F, et al.: Fatty acids, eicosanoids, and hypolipidaemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. (1997) 11:779–791.
   PubMed Web of Science ®Google Scholar
• LAMBE KG, TUGWOOD JD: A human peroxisome proliferator-activated receptor-y is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. (1996) 239:1–7.
   PubMedGoogle Scholar
• WILLSON TM, COBB JE, COWAN DJ, et al.: The structure-activity relationship between peroxisome proliferator-activated receptor y agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39:665–668.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA, et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPAR y). J. Biol. Chem. (1995) 270:12953–12956.
   PubMed Web of Science ®Google Scholar
• HENKE BR: The design synthesis and anti-hyperglycemic activity of PPAR-gamma agonists. Conference fast-track new chemical entities. Derwent Info. Serv. (1997) 5:5.
   Google Scholar
• BROWN PJ, STUART LW, HURLEY KP, et al.: Discovery of fibrate PPAR ligands. Conference fast-track new chemical entities. Derwent Info. Serv. (1997) 5:25.
   Google Scholar
• SPENCER CM, MARKHAM A: Troglitazone. Drugs (1977) 54:89–101.
   Web of Science ®Google Scholar
• HULIN B, MCCARTHY PA, GIBBS EM: The glitazone family of antidiabetic agents. Curr. Pharm. Design (1996) 2:85–102.
   Web of Science ®Google Scholar
• GROSSMAN SL, LESSEM J: Mechanisms and clinical effects of thiazolidinediones. Exp. Opin. Invest. Drugs (1997) 6:1025–1040.
   PubMedGoogle Scholar
• YOUNG PW, CRAWTHORNE MA, COYLE PJ, et al.: Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer enhances insulin action in white adipocytes. Diabetes (1995) 44:1087–1092.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, PROBSTFIELD JL, GARRISON RJ, et al.: High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 79:8–15.
   PubMed Web of Science ®Google Scholar
• FIELDING CJ, FIELDING PE: Molecular physiology of reverse cholesterol transport. J. Lipid Res. (1995) 36:211–228.
   PubMed Web of Science ®Google Scholar
• BARTER PJ, RYE KA: Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. (1996) 7:82–87.
   PubMed Web of Science ®Google Scholar
• EISENBERG S: High density lipoprotein metabolism. J. Lipid Res. (1984) 25:1017–1058.
   PubMed Web of Science ®Google Scholar
• TALL A: Plasma lipid transfer proteins. Ann. Rev. Biochem. (1995) 64:235–257.
   PubMed Web of Science ®Google Scholar
• MAROTTI KR, CASTLE CK, BOYLE TP, et al.: Severe atherosclerosis in transgenic mice expressing simian cholesterol ester transfer protein. Nature (1993) 364:73–75.
   PubMed Web of Science ®Google Scholar
• INAZU A, BROWN ML, HESLER CB, et al.: Increased high-density lipoprotein levels caused by a common cholesterol ester transfer protein gene mutation. New Engl. J. Med. (1990) 323:1234–1238.
   PubMed Web of Science ®Google Scholar
• HAYEK T, MASUCCI-MAGOULAS L, JIANG X, et al.: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesterol ester transfer protein transgene. J. Clin. Invest. (1995) 96:2071–2074.
   PubMed Web of Science ®Google Scholar
• ZHONG S, SHARP DS, GROVE JS, et al.: Increased coronary heart disease in Japanese-American men with mutation in the cholesterol ester transfer protein gene despite increased HDL levels. J. Clin. Invest. (1996) 97:2917–2923.
   PubMed Web of Science ®Google Scholar
• Miller NE, Miller GJ (Eds.), Elsevier Science Publishers, NY (1984):187–215.
   Google Scholar
• ORAM JF, ALBERS JJ, CHEUNG MC, et al.: The effects of subfractions of high density lipoprotein cholesterol efflux from cultured fibroblasts. J. Biol. Chem. (1981) 256:8348–8356.
   PubMed Web of Science ®Google Scholar
• CLAY MA, BARTER PJ: Formation of new HDL particles from lipid-free apolipoprotein A-I. J. Lipid Res. (1996) 37:1722–1732.
   PubMed Web of Science ®Google Scholar
• ORAM JF, YOKOYAMA S: Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid Res. (1996) 37:2473–2491.
   PubMed Web of Science ®Google Scholar
• MILLER NE, HAMMETT F, SALTISSI S, et al.: Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br. Med. J. (1981) 282:1741–1744.
   PubMed Web of Science ®Google Scholar
• PUCHOIS P, KANDOUSSI A, FIEVET P, et al.: Apolipoprotein A-1 containing lipoproteins in coronary artery disease. Atherosclerosis (1987) 68:35–40.
   PubMed Web of Science ®Google Scholar
• AVAGARO P, BITTOLO-BON G, CAZZOLATO G, et al.: Are apolipoproteins better discriminators than lipids for atherosclerosis Lancet (1979) 1:901–903.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI A, SAKUMA S, MORIKAWA W et al.: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1882–1888.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, CROUSE JR, KING JM, et al.: Effects of intravenous infusion of lipid-free apoAI in humans. Arterioscler. Thromb. Vasc. Biol. (1996) 16:1203–1214.
   PubMed Web of Science ®Google Scholar
• NG DS, VEZINA C, WOLEVER TS, et al.: Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics. Arterioscler. Thromb. Vasc. Biol. (1995) 15: 2157–2164.
   Google Scholar
• TALL AR: Plasma high density lipoproteins, metabolism and relationship to atherosclerosis. J. Clin. Invest. (1990) 86:379–384.
   PubMed Web of Science ®Google Scholar
• GOLDBERG IJ: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. (1996) 37:693–707.
   PubMed Web of Science ®Google Scholar
• GOLDBERG IJ, BLANER WS, VANNI TM, et al.: Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. J. Clin. Invest. (1990) 86:463–473.
   PubMed Web of Science ®Google Scholar
• MIESENBOCK G, HOLZL B, FOGER B, et al.: Heterozygous lipoprotein lipase deficiency due to missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J. Clin. Invest. (1993) 91:448–455.
   PubMed Web of Science ®Google Scholar
• SHIMADA M, ISHIBASHI S, INABA T, et al.: Suppression of diet-induced atherosclerosis in low-density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc. Natl. Acad. Sci. USA (1996) 93:7242–7246.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI K, INOUE Y, HAGI Yet al.: The novel compound NO-1886 elevates plasma HDL cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesterol ester transfer protein activity. Metabolism (1997) 46:257–260.
   PubMed Web of Science ®Google Scholar
• FRANCONE OL, HAGHPASSAND M, BENNETT JA, et al.: Expression of human lecithin:cholesterol acyltransferase in transgenic mice: effects on cholesterol eflux esterification and transport. J. Lipid Res. (1997) 38:813–822.
   PubMed Web of Science ®Google Scholar
• HOEG, JM, SANTAMARINA-FOJO S, BERARD AM, et al.: Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. USA (1996) 93:11448–11453.
   PubMed Web of Science ®Google Scholar
• MEZDOUR H, JONES R, DENGREMONT C, et al.: Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J. Biol. Chem. (1997) 272:13570–13575.
   PubMed Web of Science ®Google Scholar
• SCHISSEL SL, TWEEDIE-HARDMAN J, RAPP JH, et al.: Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein.Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. (1996) 98:1455–1464.
   PubMed Web of Science ®Google Scholar
• SCHEEK S, BROWN MS, GOLDSTEIN JL: Sphingomyelin depletion in cultured cells blocks proteolysis of sterol regulatory element binding proteins at site 1. Proc. Natl. Acad. Sci. USA (1997) 94:11179–11183.
   PubMed Web of Science ®Google Scholar
• JI Y, JIAN B, WANG N, et al.: Scavenger receptor BI promotes high-density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. (1997). 272:20982–20985.
   PubMed Web of Science ®Google Scholar
• LAGROST L: The role of cholesterol ester transfer protein and phospholipid transfer protein in the remodeling of plasma high-density lipoproteins. Trends Cardiovasc. Med. (1997) 7:218–224.
   PubMed Web of Science ®Google Scholar
• RAO R, ALBERS JJ, WOLFBAUER G, et al.: Molecular and macromolecular specificity of human plasma phospholipid transfer protein. Biochemistry (1997) 36:3645–3653.
   PubMed Web of Science ®Google Scholar
• AALTO-SETALA K, WEINSTOCK PH, BISGAIER CL, et al.: Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apo-CIII transgenic mice. J. Lipid Res. (1996) 37:1802–1811.
   PubMed Web of Science ®Google Scholar
• EBARA T, RAMAKRISHNAN R, STEINER G, et al.: Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridaemia is not mediated by effects on apolipoprotein. J. Clin. Invest. (1997) 99:2672–2681.
   PubMed Web of Science ®Google Scholar
• SCHACHTER NS, HAYEK T, LEFF T, et al.: Overexpression of apolipoprotein CII causes hypertriglyceridaemia in transgenic mice. J. Clin. Invest. (1994) 93:1683–1690.
   PubMed Web of Science ®Google Scholar
• KUHN H, CHAN L: The role of 15-lipoxygenase in atherogenesis: pro- and antiatherogenic actions. Curr. Opin. Lipidol. (1997) 8:111–117.
   PubMed Web of Science ®Google Scholar
• FEINMARK SJ, CORNICELLI JA: Is there a role for 15-lipoxygenase in atherosclerosis Biochem. Pharmacol. (1997) 54:953–959.
   Web of Science ®Google Scholar
• HURT-CAMEJO E, CAMEJO G: Potential involvement of type II phospholipase A2 in atherosclerosis. Atherosclerosis (1997) 132:1–8.
   PubMed Web of Science ®Google Scholar
• BROWN MS, GOLDSTEIN JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell (1997) 89:331–340.
   PubMed Web of Science ®Google Scholar
• STEIN JH, ROSENSON RS: Lipoprotein Lp(a) excess and coronary heart disease. Arch. Intern. Med. (1997) 157:1170–1176.
   PubMed Web of Science ®Google Scholar
• HAMILTON CA: Low-density lipoprotein and oxidized low-density lipoprotein: their role in the development of atherosclerosis. Pharmacol. Ther. (1997) 74:55–72.
   PubMed Web of Science ®Google Scholar